Skip to main content
Home / Active Studies

Active Studies

Evaluation of the effectiveness of Abrysvo® vaccine in pregnant women to prevent RSV hospitalization in their infants.

This is a collaborative study designed by iTrials - Equipo Ciencia, the Hub for Innovation in Health Policy and Equity (HubIPSE) of UNSAM, which aims to estimate the real-world impact and effectiveness of the RSVpreF vaccine (Abrysvo®, Pfizer) applied to pregnant women in the second and third trimester.
This program, called BERNI, demonstrated a high effectiveness of the vaccine in preventing hospitalizations for severe RSV-associated Acute Respiratory Infections (ARIb) during the first six months of life. This real-world and, moreover, local evidence from the first season of the program confirms and supports the findings of the MATISSE Phase 3 clinical trial.
The results of this study can be found in The Lancet.

Locations where the study is being conducted: Equipo Ciencia (Buenos Aires).

Clostridium difficile: a hidden threat behind antibiotic use

Our center has been selected to evaluate a vaccine against clostridium difficile, a bacterium that can cause serious intestinal infections, especially in older adults or people with pre-existing diseases such as COPD, heart disease, liver disease or chronic kidney disease.
This infection tends to occur more frequently in people with regular contact with the healthcare system (due to surgery, hospitalization or medical treatment) and can cause anything from mild diarrhea to more serious conditions.
Many antibiotics alter the balance between the types and quantity of bacteria living in the intestine. In this imbalance, some disease-causing bacteria can develop and replace the harmless (or even beneficial) bacteria living in the intestine, causing inflammation, increased permeability of the intestinal barrier and diarrhea.
Because clostridium difficile is becoming more and more frequent, a research study will be conducted to evaluate the efficacy, safety and tolerability of a vaccine against this bacterium, to be administered in 2 doses, with a 6-month interval between the first and the second.

Study sites:Equipo Ciencia, Osecac Sagrado Corazón, Swiss Medical Clinical Research Center, Fundación Huésped (Buenos Aires). Instituto Médico Platense (La Plata). Clínica Privada del Sol (Córdoba). Investigaciones Clínicas Salta (Salta). Clínica de Cuyo (Mendoza).

Are you interested in participating in the study? If you'd like more information…

Study of Type 2 Diabetes, Hypertension (HTN), and Established Cardiovascular Disease (CVD)

The researchers are comparing two groups of people: Group A: Takes a medication called Vicadrostato along with Empagliflozin (a common diabetes drug). Group B: Takes only Empagliflozin and a placebo.

It is specifically designed for people who have three conditions at the same time: type 2 diabetes, high blood pressure (hypertension), and established cardiovascular disease (heart attack or stroke). The goal is to demonstrate that the combination of these two medications is safe and effective in reducing the risk of death from heart-related causes, preventing the heart from weakening (preventing heart failure), and reducing the incidence of serious cardiovascular events.

Locations where the study is being conducted: Equipo Ciencia(Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

A study to evaluate a multivalent Group B Streptococcus vaccine in healthy pregnant women and their babies

This clinical trial is evaluating a new vaccine designed to protect infants against serious infections such as meningitis and sepsis. The mother receives a single dose between weeks 24 and 36 of pregnancy to generate natural defenses that are passed directly to the newborn. As a hexavalent vaccine, it offers broad coverage against the six most common variants of Group B Streptococcus bacteria. This research aims to confirm the vaccine’s safety and effectiveness to ensure a healthier start in life for children.

Study locations: Equipo Ciencia, Osecac Jonas Salk(Buenos Aires). Instituto Médico Platense (La Plata). Clínica Privada del Sol (Córdoba). Salta Public Maternal and Child Hospital(Salta). Clínica de Cuyo (Mendoza). Children and Family Clinic (Mar del Plata). Nossa Senhora de Conceição Hospital (Brazil).

Are you interested in participating in the study? If you'd like more information…

Study against COVID-19 for people with severe immunocompromise

Although SARS-CoV-2 vaccines have proven to be effective in preventing severe disease in healthy individuals, there are specific populations that require further research. Team Science will conduct a clinical trial in adults over 18 years of age, which will evaluate the efficacy and safety of a drug intended for patients with confirmed COVID-19 who are severely immunocompromised and who, precisely because of this condition, are at high risk of developing severe disease.

Locations where the study is being conducted: Osecac Sagrado Corazón (Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

New study against COVID-19 for people at risk of severe disease

Once again, Equipo Ciencia will conduct a research study focusing on SARS-CoV-2 virus infection and its complications.  

In this opportunity, the protocol will evaluate the efficacy and safety of a drug administered in adolescent and adult participants with confirmed COVID-19 who, due to pre-existing diseases, are at high risk of developing severe disease.

Study sites: Equipo Ciencia (Buenos Aires). Instituto Médico Platense (La Plata).

Are you interested in participating in the study? If you'd like more information…

Study on a new medication (CD388) to prevent the flu in people at higher risk of complications

We are launching a clinical trial designed to evaluate CD388, a new drug developed to provide protection against influenza in adults and adolescents for an entire season with a single dose.

Unlike traditional vaccines, which prepare the immune system to defend itself, this drug works by directly blocking the virus before it infects cells. This “ready-to-use protection” is particularly valuable for people with weakened immune systems or who are at high risk of complications, offering an effective alternative for those who do not respond well to conventional vaccines.

Locations where the study is being conducted: Equipo Ciencia(Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

A study to evaluate the efficacy and safety of a monoclonal antibody in participants with moderate-to-severe chronic obstructive pulmonary disease (COPD)

We are launching a Phase 3 study to evaluate the efficacy and safety of a triple inhalation therapy—a combination of three different medications in a single device—for the treatment of chronic respiratory diseases, primarily COPD (Chronic Obstructive Pulmonary Disease) and, in some cases, severe asthma. Its goal is to tackle the disease from three different angles to improve lung function and prevent flare-ups (exacerbations). The trial is intended for adult patients with a confirmed diagnosis of moderate to severe COPD.

Locations where the study is being conducted: Equipo Ciencia(Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

Early Kidney Protection: Researching How to Slow the Progression of Chronic Kidney Disease in Children Under 18

The Empa Kidney Kids study aims to evaluate the safety and efficacy of a medication called empagliflozin in children and adolescents aged 2 to 17 with chronic kidney disease. The primary objective is to observe how this drug, which is already used in adults, can help reduce protein loss in the urine and slow the progression of kidney damage. To test this, researchers will compare the outcomes of patients taking the drug with those receiving a placebo during the first 24 weeks.

Locations where the study is being conducted: Equipo Ciencia(Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

Evaluation of a new antibiotic treatment for infants and newborns with bacterial infections

This study aims to evaluate a new combination of two antibiotics (Aztreonam and Avibactam) for treating infections caused by a certain type of bacteria (called Gram-negative bacteria) in very young infants. The main goal is to understand how infants’ bodies process these medications (pharmacokinetics), how safe they are, and how well they are tolerated. The study is for infants and newborns under 9 months of age who need to be hospitalized and who have an infection (suspected or confirmed) that requires treatment with intravenous antibiotics.

Are you interested in participating in the study? If you'd like more information…

New RSV study in pregnant women: second dose and duration of protection

Following the research study that demonstrated the efficacy of the vaccine RSVpreF vaccine, which is given in the last months of pregnancy and protects infants from contracting severe respiratory RSV infection in the first months of life, Equipo Ciencia was selected to carry out a new stage of this work.

Our research center will conduct a new study that will evaluate the safety and immune response of a second dose of the vaccine in women in a new pregnancy and will study the duration of vaccine protection among women who received a single dose. A requirement for participation in this study is to have received a dose of RSV vaccine in a previous pregnancy. 

Study sites: Equipo Ciencia, Osecac Jonas Salk (Buenos Aires). Salta Public Maternal and Child Hospital (Salta). Children and Family Clinic (Mar del Plata).

Are you interested in participating in the study? If you'd like more information…

Safety Study of the Rotavirus Vaccine in Latin America

This research study, known as EPI-Rota, aims to evaluate the safety of a new version of the Rotarix vaccine (which protects against rotavirus) in infants in Latin America. The primary objective is to determine whether there is an increased risk of intussusception—a rare type of intestinal obstruction—in the days following the administration of the first and second doses. To do this, researchers will analyze the vaccination history of infants under one year of age who develop this condition and compare it with that of other healthy infants of the same age and from the same region.

The study is observational in nature, which means that neither vaccines nor placebos are administered as part of the study; instead, information is simply collected from infants who have already been vaccinated according to their countries’ official immunization schedules. The plan is to include more than 1,600 participants across several countries in the region over approximately two years. This follow-up is essential to confirm that the vaccine remains a safe and effective tool for preventing severe diarrhea caused by rotavirus in children.

Locations where the study is being conducted: Osecac Sagrado Corazón (Buenos Aires).

Are you interested in participating in the study? If you'd like more information…

If you are interested in participating in our ongoing studies, we invite you to fill out the following form:

Designed by Prod.Studio